Quazepam Dosage

Medically reviewed by Drugs.com. Last updated on Oct 10, 2024.

Applies to the following strengths: 7.5 mg; 15 mg

Usual Adult Dose for:

Insomnia

Additional dosage information:

Renal Dose Adjustments
Liver Dose Adjustments
Dose Adjustments
Precautions
Dialysis
Other Comments

Usual Adult Dose for Insomnia

Initial dose: 7.5 mg orally once a day at bedtime
Maintenance dose: 7.5 to 15 mg orally once a day at bedtime

Comments:

Prolonged administration is not recommended.
The dose may be increased to 15 mg orally at bedtime if necessary for efficacy.
The lowest effective dose should be used as adverse effects are dose related.

Use: Treatment of insomnia characterized by difficulty falling asleep, frequent nocturnal awakenings, and/or early morning awakenings

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Elderly and/or debilitated patients: Start at the lower end of the dosing range and observe closely.

Precautions

US BOXED WARNINGS:
RISKS FROM CONCOMITANT USE WITH OPIOIDS:

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.
Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.
Limit dosages and durations to the minimum required.
Follow patients for signs/symptoms of respiratory depression and sedation.

Safety and efficacy have not been established in pediatric patients.

Consult WARNINGS section for additional precautions.

US Controlled Substance: Schedule IV

Dialysis

Data not available

Other Comments

General:

Efficacy was established in placebo-controlled clinical studies performed in patients with acute and chronic insomnia over 5 nights.
Sustained efficacy in patients with chronic insomnia was established in a polysomnographic study over 28 nights.

Patient Advice:

Patients should be instructed to seek medical attention if hypersensitivity reactions occur.
Patients should be counseled to report new/unusual changes in thinking or behavior or worsening of depression.
Advise patients of next-day impairment, even in the absence of symptoms; patients should be cautioned that impairment may persist for several days following discontinuation.
Patients and caregivers of those who are taking concomitant opioid therapy should be told to immediately report profound central nervous system or respiratory depression.